Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: A systematic review and meta-analysis

OBJECTIVE: Clinical trials have shown that sodium-glucose cotransporter 2 inhibitors (SGLT2i) are closely associated with hepatic fibrosis and steatosis by FibroScan. This paper aimed at evaluating the effects of SGLT2i on hepatic fibrosis and steatosis, which are presented as liver stiffness measur...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Peipei, Tan, Ying, Hao, Zhenning, Xu, Weilong, Zhou, Xiqiao, Yu, Jiangyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014961/
https://www.ncbi.nlm.nih.gov/pubmed/36936142
http://dx.doi.org/10.3389/fendo.2023.1144838

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014961/
https://www.ncbi.nlm.nih.gov/pubmed/36936142
http://dx.doi.org/10.3389/fendo.2023.1144838

Ejemplares similares